ContactContact
Organic and inorganic growth potential from rising demand in the healthcare sector
€91.3mn
Equity investment
€186mn
Revenues 2021 (preliminary)
740
Employees 2021

KEY FACTS AT A GLANCE

  • Full range service provider in the fields of radiology and nephrology
  • Further expansion of Excellence Medicine
  • Potentials through an organic and inorganic growth strategy

EVIDIA

Investment by
DBAG FUND VII

€91.3MN

DBAG'S INTEREST

€16.3MN

MANAGEMENT BUYOUT

MINORITY
INVESTMENT OF
DBAG FUND VII

First invested

MAY 2019

REVENUES in €mn

 

95

 

2019

 

95

 

2020

 

186

 

2021 (preliminary)

As of 31 March 2022

5

add-on acquisitions closed within holding period

evidia is already the market leader in Germany in terms of the number of radiological examinations and findings. We are investing in a dynamic, innovative company with great growth potential and a clear strategic roadmap.

LUCAS HERBERT
MANAGING DIRECTOR

PROFILE

By bringing together radiological, nuclear medicine and radiotherapy practices, evidia (previously "blikk") makes an important contribution to high-quality medical care. The practices are innovative partners for patients, physicians and cooperating hospitals.

Their pioneering role in closely combining outpatient and inpatient care is rooted in many years of collaborative experience with hospitals, offering both inpatient and outpatient imaging and nuclear medicine diagnostics to patients.

Managed by operasan, the nephrology business provides patients with the complete range of modalities and treatments, including dialysis.

evidia leverages ground-breaking technologies, equipment and methods and is continuously expanding its capacities and range of medical disciplines. evidia is well positioned to tackle the challenges arising from demographic change, technological disruption and new diseases. Key competitive differentiators include the practices’ ability to provide top-class imaging and diagnostics as well as highly efficient processes and appointments at short notice.

POTENTIAL FOR DEVELOPMENT

The transaction is intended to support the sustainable organic and inorganic growth of evidia in Germany. Network advantages are important arguments for further practices to join evidia. Both doctors and patients benefit from the exchange of knowledge between medical professionals in an expert network. In addition, the practices are better positioned to jointly invest in specialists and expert staff as well as in capital-intensive equipment technology and digital systems.

The medical core process in the practices is relieved by bundling and professionalising administrative tasks. This increases quality and effectiveness. Through strategic partnerships with equipment and software providers, the Group is already a digitalisation pioneer in the radiology market and is involved in the development of AI-supported standards for everyday practice.

All this also makes evidia's practices attractive partners within the framework of existing and new hospital cooperations.

Responsible team member

Lucas Herbert
Lucas Herbert

Managing Director

Lucas Herbert
+49 69 95787-208

Lucas Herbert

Managing Director

Lucas Herbert joined Deutsche Beteiligungs AG in 2007 and became a Managing Director in 2015.

Lucas Herbert has 15 years of experience in the private equity sector. During this time, he has gained extensive knowledge, particularly in the IT services/software, mechanical and plant engineering and healthcare sectors. Lucas Herbert has been involved in a large number of corporate investments and disposals. These include Romaco, Spheros, Gienanth and Silbitz. He also led the investment process in blikk, Cloudflight and operasan.

He holds a Master of Science in Business Administration from the Rotterdam School of Management, Erasmus University, and also studied at Maastricht University and the University of Newscastle, Australia.

Current portfolio companies

evidia Cloudflight Gienanth operasan Silbitz

Former portfolio companies

Lucas Herbert

Managing Director

+49 69 95787-208